HAYWARD, Calif., Aug. 26, 2021 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced an upcoming presentation on
the effects of administering sufentanil sublingual tablet 30 mcg
(SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.
Hisham Seify, MD, PhD, FACS will
present data on the administration of SST and its effect on
reducing post-operative recovery time and opioid use in the
outpatient plastic surgery setting in patients undergoing "awake"
procedures not under general anesthesia. This new data from Dr.
Seify's study is distinct from the study previously performed by
Dr. Seify in patients under general anesthesia, which was presented
in May 2021. Dr. Seify is a
board-certified plastic surgeon and the past-president of the
Orange County Society of Plastic Surgeons. Dr. Seify is a paid
consultant for AcelRx but was not compensated for this study.
Session Title: Surgical Complications, Even the Best Laid
Plans…
Presentation Title: The Effect of the Administration of
Sublingual Sufentanil on Reducing Post-Operative Recovery Time and
Opioid Use in the Outpatient Plastic Surgery Setting
Session Date: Friday, August 27,
2021
Session Time: 11:30 AM –
1:00 PM EDT
About DSUVIA (sufentanil sublingual tablet), 30
mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in
certified medically supervised healthcare settings, such as
hospitals, surgical centers, and emergency departments, for the
management of acute pain severe enough to require an opioid
analgesic, and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile
when delivered sublingually avoids the high peak plasma levels and
short duration of action observed with IV administration. The
European Commission approved DZUVEO for marketing in Europe and it will be commercialized by
AcelRx's European partner, Aguettant.
This release is intended for investors only. For more
information, including important safety information and black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA®
(sufentanil sublingual tablet, 30 mcg), known as
DZUVEO® in Europe,
indicated for the management of acute pain severe enough to require
an opioid analgesic for adult patients in certified medically
supervised healthcare settings, and several product
candidates. The product candidates include
Zalviso® (sufentanil sublingual tablet system, SST
system, 15 mcg), an investigational product in the U.S. being
developed as an innovatively designed patient-controlled analgesia
(PCA) system for reduction of moderate-to-severe acute pain in
medically supervised settings, and two pre-filled, ready-to-use
syringes of ephedrine and phenylephrine licensed for the U.S. from
Aguettant. DZUVEO and Zalviso are both approved products in
Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/presentation-on-the-effect-of-the-administration-of-sufentanil-sublingual-tablet-on-reducing-post-operative-recovery-time-and-opioid-use-in-plastic-surgery-at-the-annual-miami-cosmetic-surgery-event-301363317.html
SOURCE AcelRx Pharmaceuticals, Inc.